A protein called MondoA has been identified by researchers at the Sanford Burnham Prebys Medical Discovery Institute (SBP) as a new potential target for drugs to prevent type 2 diabetes. Although scientific advances have led to effective strategies for preventing and treating diabetes over the past several decades, little progress has been made toward curing the disease or even getting it under control, from a public health and overall societal standpoint. Led by researchers at the University of Michigan School of Public Health, the Wellcome Trust Centre for Human Genetics at the University of Oxford, the Broad Institute of MIT and Harvard, and the Massachusetts General Hospital, more than 300 scientists from 22 countries used DNA from 120,000 individuals to pinpoint genes and their variants, which influence the disease that impacts 10 percent of the world’s population. Known as the REMIT Study, it is being led by the Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences. Type 2 diabetes affects about 8 percent Americans and another 25 percent of the population is at risk because of obesity. Recent studies using metabolomics approach coupled with statistical tools to predict incident diabetes revealed a number of metabolites that are significantly altered, including branched-chain and aromatic amino acids, such as isoleucine, leucine, valine, tyrosine and phenylalanine, as diagnostic or highly-significant predictors of future diabetes. They also demonstrated that variants in the gene TM6SF2, previously linked to hepatic steatosis (commonly known as “fatty liver”), influences risk of type 2 diabetes.
Those who would like more information about the trial can call 519 646-6100 ext. This results in diabetes as the pancreas can no longer produce enough insulin to control blood glucose.